Alpha 2.0
Login Register
» Articles » PMID: 7682448

Dose-escalation Study for the Treatment of Hodgkin's Disease. The German Hodgkin Study Group (GHSG)

Overview
Journal Ann Hematol
Specialty Hematology
Date 1993 Mar 1
PMID 7682448
Citations 5
Authors
V Diehl
Affiliations
Soon will be listed here.
Abstract

Treatment results of Hodgkin's disease have been improved by polychemotherapy. The overall cure rate for adults is about 70%. For advanced stages of Hodgkin's disease (IIIB-IV), the results of treatment are less satisfactory. One approach to improving the cure rates for patients with advanced stages is the intensification of chemotherapy. The German Hodgkin Study Group (GHSG) will apply this treatment strategy by introducing a new protocol (BEACOPP) in combination with growth factor (G-CSF) support to prevent prolonged neutropenia and severe infections. In a currently initiated "run-in"-study the maximal tolerable dose of cyclophosphamide, adriamycin, and etoposide will be defined within a multicenter setting. The subsequent trial will consist of a randomized study of BEACOPP baseline vs. BEACOPP dose-intensified vs. COPP/ABVD standard, in order to evaluate the role of dose intensification for the improvement of treatment outcome.

Citing Articles

The GHSG Approach to Treating Hodgkin's Lymphoma.

Brockelmann P, Engert A Curr Hematol Malig Rep. 2015; 10(3):256-65.

PMID: 26021610 DOI: 10.1007/s11899-015-0262-5.

Clinical Features and Prognostic Factors of Hodgkin's Lymphoma: A Single Center Experience.

Kilickap S, Barista I, Ulger S, Celik I, Selek U, Yildiz F Balkan Med J. 2014; 30(2):178-85.

PMID: 25207097 PMC: 4115978. DOI: 10.5152/balkanmedj.2012.110.

State of the art in the treatment of Hodgkin lymphoma.

Borchmann P, Eichenauer D, Engert A Nat Rev Clin Oncol. 2012; 9(8):450-9.

PMID: 22688578 DOI: 10.1038/nrclinonc.2012.91.

Treatment of Hodgkin's disease: a twenty-year follow-up of patients at a center in Korea.

Cheong J, Park S, Roh J, Suh C, Hahn J Yonsei Med J. 2006; 47(4):455-65.

PMID: 16941733 PMC: 2687724. DOI: 10.3349/ymj.2006.47.4.455.

[Pathogenesis and therapy of Hodgkin lymphoma].

Tesch H, Bohlen H, Wolf J, Engert A Med Klin (Munich). 1998; 93(2):82-90.

PMID: 9545706 DOI: 10.1007/BF03043282.

References
1.
Straus D, Gaynor J, Myers J, Merke D, Caravelli J, Chapman D . Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol. 1990; 8(7):1173-86. DOI: 10.1200/JCO.1990.8.7.1173. View
2.
Canellos G . Is there an effective salvage therapy for advanced Hodgkin's disease?. Ann Oncol. 1991; 2 Suppl 1:1-7. DOI: 10.1093/annonc/2.suppl_1.1. View
3.
De Vita Jr V, Hubbard S, Longo D . The chemotherapy of lymphomas: looking back, moving forward--the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res. 1987; 47(22):5810-24. View